Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 6Recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Hepatic Impairment 1

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × tazemetostat × Clear all
NCT05618366 2026-04-02

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Weill Medical College of Cornell University

Phase 1 Terminated
3 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡